Diabetes

Jennifer Goldman, PharmD, RPh, CDCES, BC-ADM, FCCP, shares the history and mission of NEIAP and explains how the organization provides practical education and networking opportunities.

In addition to explaining how NEIAP has evolved over time, Katelyn O'Brien, PharmD, BCPS, CDCES, BC-ADM, previews key topics at the upcoming September meeting.

Findings from a multicenter cohort study suggest glucagon-like peptide-1 (GLP-1) receptor agonist therapy may be associated with an elevated risk of sensory disturbances.

Phase 3 REIMAGINE data presented at ADA 2026 show the amylin–GLP-1 combination bests semaglutide monotherapy across type 2 diabetes stages, with implications for pharmacist-managed diabetes care.

The integrated CGM is now indicated for individuals 2 years and older who do not use insulin.

Approval of teplizumab-mzwv in patients aged 8 to 17 years makes it the first disease-modifying therapy for children newly diagnosed with stage 3 type 1 diabetes.

Pharmacy Times speaks with Joyce Lee, PharmD, APh, FCCP, BCPS, BCACP, CDCES, to breakdown the diabetes education gap that clinicians can't afford to ignore.

A landmark joint guideline on cardiovascular-kidney-metabolic syndrome offers clinicians a comprehensive, stage-based road map for screening, prevention, and treatment of an increasingly prevalent interconnected condition.

Disparities in education access and quality, income level, and race and ethnicity are SDoH that make a major impact on diabetes and its management in the US.

Afrezza is the only ultra rapid-acting inhaled insulin approved by the FDA to improve glycemic control in children, adolescent, and adult patients with diabetes.

In an interview with Pharmacy Times at the Consortium of Multiple Sclerosis Centers 2026, Donald Langan, PharmD, MD, a Multiple Sclerosis and Clinical Neuroimmunology Fellow at Columbia University, presenting on the evolution of GLP-1 receptor agonists, discussed the future of GLP-1 therapies and the expansion of the pharmacist's role.

As Novo Nordisk transitions patients from Rybelsus to newer, higher-efficacy oral semaglutide formulations, pharmacists are on the front lines of counseling, dosing clarification, and adverse effect management.

Community pharmacists emerged as the critical clinical link in the modern patient care continuum

Susan Cornell, PharmD, CDCES, FAPhA, FADCES, explains how pharmacists should approach continuous glucose monitoring (CGM) report review and explains why individualized patient education is key.

Amy Hess-Fischl, MS, RDN, LDN, BC-ADM, CDCES, explains how pharmacists can better leverage underutilized continuous glucose monitoring (CGM) app features and address the education gaps that prevent patients from achieving long-term CGM persistence.

Nicole C. Pezzino, PharmD, BCACP, CDCES, explains why reimbursement gaps, workflow constraints, and the emotional burden of wearing a continuous glucose monitor (CGM) are limiting CGM success and how pharmacists can improve outcomes.

Diana Isaacs, PharmD, BCACP, BC-ADM, CDCES, FADCES, FCCP, explores the most significant advancements in continuous glucose monitoring (CGM) and automated insulin delivery in 2026.

Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, discusses how continuous glucose monitoring (CGM) technology and automated insulin delivery systems are transforming pharmacists’ roles.

Natalie Bellini, DNP, FNP-BC, BC-ADM, explains why continuous glucose monitor (CGM) persistence so often breaks down after initiation and how pharmacists can intervene at the point of dispensing.

Rapid insulin discontinuation occurred with tirzepatide 2.5 mg weekly in long-standing type 2 diabetes, demonstrating a low-dose responder phenotype and pharmacist-led CGM-guided deprescribing.

FDA Recall targets True Metrix blood glucose monitoring systems after E-5 errors risk mistreating diabetes; updated guidance helps patients, pharmacists prevent harm.

Integrated pharmacist-led care models help to improve diabetes outcomes, expand CGM use, and reduce costs through proactive, multidisciplinary patient management.

GLP-1 weight-loss drugs reshape healthcare and consumer spending, as markets surge, coverage splits, and subscription models spread.

FDA expands teplizumab to age 1 year for stage 2 type 1 diabetes—pharmacists must learn dosing, infusion logistics, and safety monitoring.

The interchangeable designation allows pharmacists to substitute Langlara for Lantus at the point of dispensing without prescriber intervention, a distinction that carries significant clinical and operational implications for pharmacy practice.